Report Highlights

Submucosal Injections in the United States: Market Overview

The U.S. submucosal injections market supplies lifting agents, including sodium hyaluronate, glycerol and sterile saline, used to elevate lesions during endoscopic mucosal resection and endoscopic submucosal dissection. The market was valued at US$310 million in 2024 and forms a specialised niche within the broader endoscopy consumables segment. Unlike the global norm, where Asian hospitals drive volume through gastric ESD, U.S. demand is anchored in colorectal polypectomy performed by gastroenterology practices.

Procedure volume is the primary structural driver. Colorectal polypectomy and EMR for lesions above 10 millimetres account for most units consumed, while ESD remains confined to a small number of high-volume academic centres. Pricing is set largely through Medicare outpatient payment rules and hospital group purchasing contracts, which keeps average selling prices lower than in Japan, where reimbursement favours device-intensive resection.

Growth Drivers in U.S. Submucosal Injections

The USPSTF lowered the recommended colorectal cancer screening age to 45 in 2021, expanding the eligible population by roughly 19 million adults according to American Cancer Society estimates. Each positive screen generates polypectomy, and larger adenomas require lifting agents before resection. Medicare coverage of screening colonoscopy under Section 1861(pp) of the Social Security Act anchors this demand at the federal level.

Regulatory and reimbursement shifts reinforce this demand. CMS has progressively added gastrointestinal endoscopic procedures to the Ambulatory Surgery Center Covered Procedures List, allowing operators to move lifting-agent use from hospital outpatient departments into lower-cost ASC settings. Academic adoption of ESD, supported by training programmes at the Mayo Clinic and Cleveland Clinic, is gradually diffusing advanced techniques into community practice.

Market Restraints and Entry Barriers in the United States

FDA premarket clearance is the first barrier. Most lifting agents are regulated as devices under 510(k), while products combining a drug component fall under the PMA pathway, so entrants should expect review timelines of several months plus extensive labelling negotiation. Gastroenterologists also require endoscopist-level clinical evidence before switching from an established product, which lengthens commercial adoption cycles.

Hospital value analysis committees and group purchasing contracts with Vizient and Premier create incumbency advantages that are difficult to dislodge. Medicare's bundled payment structure for endoscopic resection means hospitals absorb consumable costs without separate reimbursement, which pushes purchasing toward the lowest-cost saline option regardless of clinical preference.

Market Opportunities in the United States

Ambulatory surgery centres represent the nearest growth pocket. The U.S. operates more than 5,000 Medicare-certified ASCs, and gastroenterology is among the fastest-growing specialties within them. A single-use, pre-packaged lifting kit priced for ASC procedure trays addresses an underserved segment estimated at US$60 million annually, based on analyst estimates of procedure volumes.

Community hospitals performing EMR without dedicated ESD capability form a second opportunity. Analyst estimates place U.S. endoscopic resections above 1.2 million annually, and premium hyaluronic acid agents could capture roughly US$85 million in community settings by 2028. Targeted clinical education programmes would accelerate conversion from saline-based protocols.

Market at a Glance

Leading Market Participants

• Boston Scientific
• Olympus Corporation of the Americas
• Cook Medical
• Fujifilm Healthcare Americas
• HOYA PENTAX Medical
• Cosmo Pharmaceuticals
• Aries Pharmaceuticals
• Ethicon
• Medtronic
• Merit Medical Systems

Regulatory and Policy Environment

The FDA oversees lifting agents under the Federal Food, Drug, and Cosmetic Act, with most devices cleared through 510(k) and combination products through PMA. Manufacturers must also meet Quality System Regulation requirements under 21 CFR Part 820, which the FDA is aligning with ISO 13485 as the Quality Management System Regulation takes effect in February 2026.

Reimbursement is governed by CMS through the Hospital Outpatient Prospective Payment System and the ambulatory surgery center payment system, updated annually via the Medicare Physician Fee Schedule and OPPS rulemaking. The Medical Device User Fee Amendments (MDUFA V) fund FDA review timelines through 2027, and manufacturers should track CMS proposed rules published each summer.

Long-Term Outlook for U.S. Submucosal Injections

By 2032 the market is forecast to reach US$527 million, growing at a 6.8% CAGR from the 2025 base year. Growth will concentrate in ASC channels, which are projected to overtake hospital outpatient departments as the largest purchasing channel for lifting agents by 2029.

Product mix will shift toward premium hyaluronic acid and hemostatic gel formulations as payers and hospital systems reward lower bleeding and perforation rates. Saline will retain volume in price-sensitive hospitals, while consolidation among gastroenterology practice management groups will tighten supplier negotiations through the forecast period.